Emergent Biosolutions, Inc. (EBS) Position Lowered by Foundry Partners LLC
Foundry Partners LLC cut its stake in shares of Emergent Biosolutions, Inc. (NYSE:EBS) by 5.4% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 91,508 shares of the biopharmaceutical company’s stock after selling 5,262 shares during the period. Foundry Partners LLC’s holdings in Emergent Biosolutions were worth $3,103,000 at the end of the most recent reporting period.
Several other hedge funds also recently made changes to their positions in the stock. Norges Bank bought a new stake in shares of Emergent Biosolutions during the fourth quarter valued at approximately $12,364,000. Aberdeen Asset Management PLC UK boosted its stake in shares of Emergent Biosolutions by 29.6% in the first quarter. Aberdeen Asset Management PLC UK now owns 1,618,576 shares of the biopharmaceutical company’s stock valued at $47,003,000 after buying an additional 369,908 shares during the period. Vanguard Group Inc. boosted its stake in shares of Emergent Biosolutions by 6.7% in the first quarter. Vanguard Group Inc. now owns 3,773,200 shares of the biopharmaceutical company’s stock valued at $109,574,000 after buying an additional 238,194 shares during the period. State Street Corp boosted its stake in shares of Emergent Biosolutions by 17.2% in the first quarter. State Street Corp now owns 1,452,472 shares of the biopharmaceutical company’s stock valued at $42,180,000 after buying an additional 213,500 shares during the period. Finally, Snyder Capital Management L P boosted its stake in shares of Emergent Biosolutions by 17.8% in the first quarter. Snyder Capital Management L P now owns 1,134,332 shares of the biopharmaceutical company’s stock valued at $32,941,000 after buying an additional 171,636 shares during the period. Hedge funds and other institutional investors own 85.54% of the company’s stock.
Emergent Biosolutions, Inc. (NYSE:EBS) opened at 36.10 on Wednesday. The firm has a market cap of $1.49 billion, a PE ratio of 22.99 and a beta of 1.22. The firm’s 50-day moving average is $34.91 and its 200-day moving average is $31.60. Emergent Biosolutions, Inc. has a 12 month low of $24.47 and a 12 month high of $36.95.
Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.13 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.26 by $0.13. Emergent Biosolutions had a net margin of 13.42% and a return on equity of 14.50%. The business had revenue of $100.77 million during the quarter, compared to analyst estimates of $111.57 million. During the same period in the previous year, the company posted ($0.05) earnings per share. Emergent Biosolutions’s revenue was up 10.4% compared to the same quarter last year. Equities analysts expect that Emergent Biosolutions, Inc. will post $1.55 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/emergent-biosolutions-inc-ebs-position-lowered-by-foundry-partners-llc/1493750.html.
A number of equities analysts have issued reports on EBS shares. Zacks Investment Research cut shares of Emergent Biosolutions from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. BidaskClub upgraded shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $44.00.
In other Emergent Biosolutions news, Chairman Fuad El-Hibri sold 25,000 shares of the company’s stock in a transaction dated Thursday, July 27th. The shares were sold at an average price of $36.50, for a total value of $912,500.00. Following the completion of the sale, the chairman now directly owns 1,630,216 shares of the company’s stock, valued at approximately $59,502,884. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 16.50% of the stock is currently owned by corporate insiders.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions, Inc. (NYSE:EBS).
Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.